Background: Recent studies have reported findings regarding the addition of pegylated interferon aligned -alpha (Peg- IFNα) to nucleos (t) analog ideas. This study was designed to compare the efficacy of Peg- IFNα therapy and tenofovir disoproxil fumarate (TDF) in combination with each treatment separately.
Methods: In this open-label, randomized clinical trial, treatment-naive hepatitis B e antigen (HBeAg) -negative patients were randomly assigned to three treatment groups: Group A: Peg- IFNα (180 mcg / week) with TDF (300 mg / day); Group B: TDF (300 mg / day); and Group C: Peg- IFNα (180 mcg / week). intervention runs 48 weeks and patients were followed every 12 weeks. Primary endpoint was the burden of HBV DNA <20 IU / mL.
Results : Group A, B and C, each consisting of 22, 23 and 22 patients, respectively. The number of patients with HBV DNA suppression in group A was significantly higher than in group B and C (P = 0.034). No significant differences were observed in the trend of normalization of serum ALT levels between the three groups (P = 0.082). At week 48, the combination therapy was significantly more effective in suppressing HBV DNA concentrations below detection levels of TDF monotherapy (OR = 2.1, 95% CI: 1.18 to 4.15; P = 0.034). In addition, the comparison between the monotherapy arm revealed that both interventions have the same effect on the overall outcome (OR = 1.24, 95% CI: 1.02 to 5.8; P = 0.062).
Conclusion: A Peg- IFNα and TDF combination therapy resulted in a good and safe virologic response in patients with HBeAg negative. Monotherapy with Peg-IFNα or TDF benefit was limited compared.
A randomized controlled trial of pegylated interferon-alpha with tenofovir disoproxil fumarate for hepatitis B e antigen-negative chronic hepatitis B: A 48-week follow-up study
Double-blind, randomized trial to compare the efficacy of escitalopram compared to citalopram for depression induced interferon in patients with hepatitis C
Objective: The objective of this study was to compare two antidepressant drug citalopram and escitalopram on the basis of success in depressed patients of hepatitis C patients who received interferon.
Methods: In a double-blind randomized trial, patients with hepatitis C visit the National institute liver and gastro intestinal diseases (NILGID), Dow University Hospital, screened for depression before starting treatment with interferon. Institutional review board approval was obtained and references no.is mail: IRB-682 / DUHS / approval / 2016/169. Patients with a history of depression were excluded from the study. The patients who started therapy with interferon assessed for depression at baseline and then at each visit. Those who develop depression were randomly assigned to receive either citalopram or escitalopram. treatment groups was assessed by a scale of depression every time they visit the clinic. Two antidepressants compared to their success in an interval of 4 weeks, 8weeks and then 12 weeks.
IFNA16 ORF Vector (Human) (pORF)
ORF021358
ABM
1.0 ug DNA
Ask for price
IFNA4 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV)
LV647509
ABM
1.0 ug DNA
EUR 616.8
IFNA4 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC)
LV647513
ABM
1.0 ug DNA
EUR 616.8
IFNA1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV)
LV683185
ABM
1.0 ug DNA
EUR 616.8
IFNA1 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC)
LV683189
ABM
1.0 ug DNA
EUR 616.8
IFNA20P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)
LV729275
ABM
1.0 ug DNA
Ask for price
IFNA20P Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC)
LV729279
ABM
1.0 ug DNA
Ask for price
IFNA11P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)
LV763643
ABM
1.0 ug DNA
EUR 1173.6
IFNA11P Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC)
LV763647
ABM
1.0 ug DNA
EUR 1173.6
IFNA12P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)
LV763649
ABM
1.0 ug DNA
EUR 1173.6
IFNA12P Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC)
LV763653
ABM
1.0 ug DNA
EUR 1173.6
IFNA22P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)
LV763655
ABM
1.0 ug DNA
EUR 1173.6
IFNA22P Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC)
LV763659
ABM
1.0 ug DNA
EUR 1173.6
IFNA4 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a)
LV647514
ABM
1.0 ug DNA
EUR 616.8
IFNA4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)
LV706467
ABM
1.0 ug DNA
EUR 540
IFNA4 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC)
LV706471
ABM
1.0 ug DNA
EUR 540
IFNA1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)
LV706491
ABM
1.0 ug DNA
EUR 540
IFNA1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC)
LV706495
ABM
1.0 ug DNA
EUR 540
IFNA1 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a)
LV683190
ABM
1.0 ug DNA
EUR 616.8
IFNA20P Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a)
LV729280
ABM
1.0 ug DNA
Ask for price
IFNA11P Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a)
LV763648
ABM
1.0 ug DNA
EUR 1173.6
IFNA12P Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a)
LV763654
ABM
1.0 ug DNA
EUR 1173.6
IFNA22P Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a)
LV763660
ABM
1.0 ug DNA
EUR 1173.6
IFNA4 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a)
LV706472
ABM
1.0 ug DNA
EUR 540
IFNA1 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a)
LV706496
ABM
1.0 ug DNA
EUR 540
IFNA13 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)
LV791922
ABM
1.0 ug DNA
EUR 448.8
IFNA4 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA)
LV647510
ABM
1.0 ug DNA
EUR 616.8
IFNA1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA)
LV683186
ABM
1.0 ug DNA
EUR 616.8
IFNA20P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA)
LV729276
ABM
1.0 ug DNA
Ask for price
IFNA11P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA)
LV763644
ABM
1.0 ug DNA
EUR 1173.6
IFNA12P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA)
LV763650
ABM
1.0 ug DNA
EUR 1173.6
IFNA22P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA)
LV763656
ABM
1.0 ug DNA
EUR 1173.6
IFNA20P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)
LV729277
ABM
1.0 ug DNA
Ask for price
IFNA20P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)
LV729278
ABM
1.0 ug DNA
Ask for price
IFNA11P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)
LV763645
ABM
1.0 ug DNA
EUR 1243.2
IFNA11P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)
LV763646
ABM
1.0 ug DNA
EUR 1243.2
IFNA12P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)
LV763651
ABM
1.0 ug DNA
EUR 1243.2
IFNA12P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)
LV763652
ABM
1.0 ug DNA
EUR 1243.2
IFNA22P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)
LV763657
ABM
1.0 ug DNA
EUR 1243.2
IFNA22P Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)
LV763658
ABM
1.0 ug DNA
EUR 1243.2
IFNA4 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)
LV647511
ABM
1.0 ug DNA
EUR 686.4
IFNA4 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)
LV647512
ABM
1.0 ug DNA
EUR 686.4
IFNA4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA)
LV706468
ABM
1.0 ug DNA
EUR 540
IFNA1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA)
LV706492
ABM
1.0 ug DNA
EUR 540
IFNA1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)
LV683187
ABM
1.0 ug DNA
EUR 686.4
IFNA1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)
LV683188
ABM
1.0 ug DNA
EUR 686.4
IFNA4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)
LV706469
ABM
1.0 ug DNA
EUR 609.6
IFNA4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)
LV706470
ABM
1.0 ug DNA
EUR 609.6
IFNA1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)
LV706493
ABM
1.0 ug DNA
EUR 609.6
IFNA1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)
LV706494
ABM
1.0 ug DNA
EUR 609.6
IFNA16 Protein Vector (Human) (pPM-C-HA)
PV085431
ABM
500 ng
Ask for price
IFNA17 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector
TL303989
Origene Technologies GmbH
5 µg/vial
Ask for price
Ifna11 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector
TL501045
Origene Technologies GmbH
5 µg/vial
Ask for price
IFNA21 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector
TL315496
Origene Technologies GmbH
5 µg/vial
Ask for price
Ifna13 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector
TL506870
Origene Technologies GmbH
5 µg/vial
Ask for price
Ifna12 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector
TL507368
Origene Technologies GmbH
5 µg/vial
Ask for price
Ifna15 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector
TL514892
Origene Technologies GmbH
5 µg/vial
Ask for price
Ifna14 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector
TL512221
Origene Technologies GmbH
5 µg/vial
Ask for price
IFNA14 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector
TL312238
Origene Technologies GmbH
5 µg/vial
Ask for price
IFNA13 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector
TL312239
Origene Technologies GmbH
5 µg/vial
Ask for price
IFNA10 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector
TL312240
Origene Technologies GmbH
5 µg/vial
Ask for price
IFNA16 Protein Vector (Human) (pPB-C-His)
PV085429
ABM
500 ng
Ask for price
IFNA16 Protein Vector (Human) (pPB-N-His)
PV085430
ABM
500 ng
Ask for price
IFNA16 Protein Vector (Human) (pPM-C-His)
PV085432
ABM
500 ng
Ask for price
IFNA7 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector
TL303986
Origene Technologies GmbH
5 µg/vial
Ask for price
IFNA6 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector
TL303987
Origene Technologies GmbH
5 µg/vial
Ask for price
IFNA4 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector
TL303988
Origene Technologies GmbH
5 µg/vial
Ask for price
IFNA1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector
TL303990
Origene Technologies GmbH
5 µg/vial
Ask for price
Ifna1 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector
TL501044
Origene Technologies GmbH
5 µg/vial
Ask for price
Ifna2 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector
TL501046
Origene Technologies GmbH
5 µg/vial
Ask for price
Ifna5 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector
TL501047
Origene Technologies GmbH
5 µg/vial
Ask for price
Ifna7 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector
TL501049
Origene Technologies GmbH
5 µg/vial
Ask for price
Ifna9 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector
TL512618
Origene Technologies GmbH
5 µg/vial
Ask for price
Ifna6 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector
TL508669
Origene Technologies GmbH
5 µg/vial
Ask for price
Ifna4 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector
TL509418
Origene Technologies GmbH
5 µg/vial
Ask for price
IFNA8 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector
TL312234
Origene Technologies GmbH
5 µg/vial
Ask for price
IFNA5 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector
TL312235
Origene Technologies GmbH
5 µg/vial
Ask for price
IFNA2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector
TL312236
Origene Technologies GmbH
5 µg/vial
Ask for price
IFNA16 siRNA
20-abx920220
Abbexa
IFNAR1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV)
LV640375
ABM
1.0 ug DNA
EUR 818.4
IFNAR1 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC)
LV640379
ABM
1.0 ug DNA
EUR 818.4
IFNA16 Antibody
37641-100ul
SAB
100ul
EUR 302.4
IFNA16 Antibody
1-CSB-PA689914
Cusabio
Description: A polyclonal antibody against IFNA16. Recognizes IFNA16 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB;ELISA:1:2000-1:5000, WB:1:500-1:2000
IFNA16 Antibody
1-CSB-PA011036LA01HU
Cusabio
Description: A polyclonal antibody against IFNA16. Recognizes IFNA16 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC; Recommended dilution: IHC:1:20-1:200
IFNA16 Antibody
E037641
EnoGene
100μg/100μl
EUR 255
Description: Available in various conjugation types.
IFNA16 Antibody
37641
SAB
100ul
EUR 319
IFNAR1 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a)
LV640380
ABM
1.0 ug DNA
EUR 818.4
IFNA16 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
TL312237V
Origene Technologies GmbH
500 ul each
Ask for price
IFNA16 sgRNA CRISPR Lentivector set (Human)
K1020001
ABM
3 x 1.0 ug
EUR 406.8
IFNA16 Rabbit pAb
E2161774
EnoGene
100ul
EUR 225
Description: Available in various conjugation types.
IFNA16 sgRNA CRISPR Lentivector (Human) (Target 1)
K1020002
ABM
1.0 ug DNA
EUR 184.8
IFNA16 sgRNA CRISPR Lentivector (Human) (Target 2)
K1020003
ABM
1.0 ug DNA
EUR 184.8
IFNA16 sgRNA CRISPR Lentivector (Human) (Target 3)
K1020004
ABM
1.0 ug DNA
EUR 184.8
IFNA16 Conjugated Antibody
C37641
SAB
100ul
EUR 476.4
IFNAR1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA)
LV640376
ABM
1.0 ug DNA
EUR 818.4
Lenti ORF particles, IFNA16 (mGFP-tagged) - Human interferon, alpha 16 (IFNA16), 200ul, >10^7 TU/mL
RC214713L2V
Origene Technologies GmbH
200 µl
Ask for price
Lenti ORF particles, IFNA16 (mGFP-tagged) - Human interferon, alpha 16 (IFNA16), 200ul, >10^7 TU/mL
RC214713L4V
Origene Technologies GmbH
200 µl
Ask for price
IFNA16 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector
TR312237
Origene Technologies GmbH
5 µg/vial
Ask for price
IFNAR1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)
LV640377
ABM
1.0 ug DNA
EUR 888
IFNAR1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)
LV640378
ABM
1.0 ug DNA
EUR 888
Lenti ORF particles, IFNA16 (Myc-DDK tagged) - Human interferon, alpha 16 (IFNA16), 200ul, >10^7 TU/mL
RC214713L1V
Origene Technologies GmbH
200 µl
Ask for price
Lenti ORF particles, IFNA16 (Myc-DDK tagged) - Human interferon, alpha 16 (IFNA16), 200ul, >10^7 TU/mL
RC214713L3V
Origene Technologies GmbH
200 µl
Ask for price
Ifnar1 - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector
TL704488
Origene Technologies GmbH
5 µg/vial
Ask for price
Ifnab - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector
TL501050
Origene Technologies GmbH
5 µg/vial
Ask for price
Human IFNA16 shRNA Plasmid
20-abx952338
Abbexa
IFNAR2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector
TL303985
Origene Technologies GmbH
5 µg/vial
Ask for price
Ifnar2 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector
TL511856
Origene Technologies GmbH
5 µg/vial
Ask for price
Ifnar1 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector
TL509551
Origene Technologies GmbH
5 µg/vial
Ask for price
IFNAR1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector
TL312233
Origene Technologies GmbH
5 µg/vial
Ask for price
IFNA16 Antibody, HRP conjugated
1-CSB-PA011036LB01HU
Cusabio
Description: A polyclonal antibody against IFNA16. Recognizes IFNA16 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA
IFNA16 Antibody, FITC conjugated
1-CSB-PA011036LC01HU
Cusabio
Description: A polyclonal antibody against IFNA16. Recognizes IFNA16 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA
IFNA16 Antibody, Biotin conjugated
1-CSB-PA011036LD01HU
Cusabio
Description: A polyclonal antibody against IFNA16. Recognizes IFNA16 from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA
Human IFNA16 knockout cell line
ABC-KH7185
AcceGen
1 vial
Ask for price
Description: Human IFNA16 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology.
IFNA16 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human)
K1020005
ABM
3 x 1.0 ug
EUR 451.2
Human IFNA16 Protein Lysate 20ug
IHUIFNA16PLLY20UG
Innovative research
each
EUR 213
Description: Human IFNA16 Protein Lysate 20ug
Human IFNA16 knockdown cell line
ABC-KD7185
AcceGen
1 vial
Ask for price
Description: Human IFNA16 knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest.
Interferon Alpha 16 (IFNA16) Antibody
20-abx211357
Abbexa
Ifna16 - Mouse, 4 unique 29mer shRNA constructs in retroviral untagged vectorr
TR506871
Origene Technologies GmbH
5 µg/vial
Ask for price
Recombinant Interferon Alpha 16 (IFNa16)
4-RPG968Mu01
Cloud-Clone
EUR 636.10
EUR 294.00
EUR 2055.36
EUR 765.12
EUR 1410.24
EUR 501.60
EUR 4958.40
100 ug
10ug
1 mg
200 ug
500 ug
50ug
5 mg
Description: Recombinant Mouse Interferon Alpha 16 expressed in: E.coli
Recombinant Interferon Alpha 16 (IFNa16)
RPG968Mu01
Cloud-Clone
10ug
EUR 192
IFNA16 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1)
K1020006
ABM
1.0 ug DNA
EUR 200.4
IFNA16 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2)
K1020007
ABM
1.0 ug DNA
EUR 200.4
IFNA16 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3)
K1020008
ABM
1.0 ug DNA
EUR 200.4
IFNA16 3'UTR GFP Stable Cell Line
TU060478
ABM
1.0 ml
EUR 1672.8
Recombinant Human Interferon alpha-16 (IFNA16)
CSB-EP011036HU
Cusabio
7794 mg
Ask for price
Recombinant Human Interferon alpha-16 (IFNA16)
CSB-YP011036HU
Cusabio
10567 mg
Ask for price
IFNA16 3'UTR Luciferase Stable Cell Line
TU010478
ABM
1.0 ml
EUR 1672.8
Human Interferon alpha- 16, IFNA16 ELISA KIT
ELI-48218h
Lifescience Market
96 Tests
EUR 988.8
Human Interferon Alpha 16 (IFNa16) Protein (Active)
20-abx655681
Abbexa
EUR 1345.20
EUR 493.20
EUR 4468.80
EUR 1629.60
EUR 910.80
100 ug
10 ug
1 mg
200 ug
50 ug
ARP60735_P050-25UL - IFNA16 Antibody - C-terminal region
ARP60735_P050-25UL
Aviva Systems Biology
25ul
EUR 99
Lenti ORF clone of Human interferon, alpha 16 (IFNA16), Myc-DDK-tagged
RC214713L1
Origene Technologies GmbH
10 µg
Ask for price
Lenti ORF clone of Human interferon, alpha 16 (IFNA16), Myc-DDK-tagged
RC214713L3
Origene Technologies GmbH
10 µg
Ask for price
ARP60735_P050 - IFNA16 Antibody - C-terminal region (ARP60735_P050)
ARP60735_P050
Aviva Systems Biology
100ul
EUR 389
h IFNAR2 inducible lentiviral particles
LVP774
GenTarget
1x107 IFU/ml x 200ul
EUR 541.2
Description: Pre-made over-expression lentivirus for expressing human target: IFNAR2 (interferon (alpha, beta and omega) receptor 2), [alternative names: IFN-alpha-REC; IFN-R; IFNABR; IFNARB]. The sub-cloned codon sequence is identical (100% match) to CDS region in NCBI ID: NM_207585.2. It also contains a RFP-Blasticidin dual selection marker.
IFNA17 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
TL303989V
Origene Technologies GmbH
500 ul each
Ask for price
Ifna11 - Mouse shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
TL501045V
Origene Technologies GmbH
500 ul each
Ask for price
IFNA21 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
TL315496V
Origene Technologies GmbH
500 ul each
Ask for price
Ifna13 - Mouse shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
TL506870V
Origene Technologies GmbH
500 ul each
Ask for price
Ifna12 - Mouse shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
TL507368V
Origene Technologies GmbH
500 ul each
Ask for price
Ifna14 - Mouse shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
TL512221V
Origene Technologies GmbH
500 ul each
Ask for price
IFNA14 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
TL312238V
Origene Technologies GmbH
500 ul each
Ask for price
IFNA13 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
TL312239V
Origene Technologies GmbH
500 ul each
Ask for price
IFNA10 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
TL312240V
Origene Technologies GmbH
500 ul each
Ask for price
IFNA7 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
TL303986V
Origene Technologies GmbH
500 ul each
Ask for price
IFNA6 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
TL303987V
Origene Technologies GmbH
500 ul each
Ask for price
IFNA4 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
TL303988V
Origene Technologies GmbH
500 ul each
Ask for price
IFNA1 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
TL303990V
Origene Technologies GmbH
500 ul each
Ask for price
Ifna1 - Mouse shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
TL501044V
Origene Technologies GmbH
500 ul each
Ask for price
Ifna2 - Mouse shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
TL501046V
Origene Technologies GmbH
500 ul each
Ask for price
Ifna5 - Mouse shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
TL501047V
Origene Technologies GmbH
500 ul each
Ask for price
Ifna7 - Mouse shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
TL501049V
Origene Technologies GmbH
500 ul each
Ask for price
Ifna9 - Mouse shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
TL512618V
Origene Technologies GmbH
500 ul each
Ask for price
Ifna6 - Mouse shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
TL508669V
Origene Technologies GmbH
500 ul each
Ask for price
Ifna4 - Mouse shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
TL509418V
Origene Technologies GmbH
500 ul each
Ask for price
IFNA8 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
TL312234V
Origene Technologies GmbH
500 ul each
Ask for price
IFNA5 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
TL312235V
Origene Technologies GmbH
500 ul each
Ask for price
IFNA2 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
TL312236V
Origene Technologies GmbH
500 ul each
Ask for price
IFNA13 ORF Vector (Human) (pORF)
ORF005213
ABM
1.0 ug DNA
EUR 114
IFNA21 ORF Vector (Human) (pORF)
ORF005214
ABM
1.0 ug DNA
EUR 114
IFNA10 ORF Vector (Human) (pORF)
ORF013324
ABM
1.0 ug DNA
EUR 424.8
IFNA14 ORF Vector (Human) (pORF)
ORF021357
ABM
1.0 ug DNA
EUR 486
IFNA17 ORF Vector (Human) (pORF)
ORF021359
ABM
1.0 ug DNA
EUR 486
Ifna11 ORF Vector (Mouse) (pORF)
ORF047683
ABM
1.0 ug DNA
EUR 607.2
Ifna12 ORF Vector (Mouse) (pORF)
ORF047684
ABM
1.0 ug DNA
EUR 607.2
Ifna13 ORF Vector (Mouse) (pORF)
ORF047685
ABM
1.0 ug DNA
EUR 607.2
Ifna14 ORF Vector (Mouse) (pORF)
ORF047686
ABM
1.0 ug DNA
EUR 607.2
IFNA11P ORF Vector (Human) (pORF)
ORF021355
ABM
1.0 ug DNA
Ask for price
IFNA12P ORF Vector (Human) (pORF)
ORF021356
ABM
1.0 ug DNA
Ask for price
IFNA20P ORF Vector (Human) (pORF)
ORF021361
ABM
1.0 ug DNA
Ask for price
IFNA22P ORF Vector (Human) (pORF)
ORF021362
ABM
1.0 ug DNA
Ask for price
Ifna1 ORF Vector (Rat) (pORF)
ORF068513
ABM
1.0 ug DNA
EUR 607.2
Ifna4 ORF Vector (Rat) (pORF)
ORF068514
ABM
1.0 ug DNA
EUR 607.2
IFNA13 Protein Vector (Human) (pPM-C-HA)
PV020851
ABM
500 ng
EUR 394.8
IFNA21 Protein Vector (Human) (pPM-C-HA)
PV020855
ABM
500 ng
EUR 394.8
Results: In the present study 80 patients were randomized to receive either citalopram or escitalopram. The research result was better in patients treated with escitalopram. Significant changes in depression scores from the beginning to the end of the study was greater in the escitalopram group is 10.41 compared with citalopram group is 14.17. Differences in depression scores were also calculated as 4.28 and.3.76 (p <0.001) for both drugs at week 8 and week 12 respectively, which were statistically significant. Difference in depression scores were also calculated for the sex of 0.576 (p = 0.497) and age of 0.950 (p = 0.265), were found to be significant, statistically.
Conclusion: The results show the superiority of escitalopram over citalopram, the drug is twice as potent as racemic mixtures. In addition the drug is well tolerated and showed a better effect. Escitalopram proven to be a safer alternative to citalopram.